The UK and US have announced a major trade agreement that will preserve no levies on UK drug products being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on pharmaceuticals through the NHS. This move guarantees that import taxes on these crucial goods will be held at zero for a timeframe of 36 months.
This development is in response to previous threats to significantly raise import taxes on patented drug products, with potential rates discussed up to one hundred percent.
"This deal between the UK strengthens the worldwide climate for innovative medicines and establishes long-overdue fairness to transatlantic drug exports," a statement noted.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's largest export categories to the United States, which is clearly the largest buyer for large UK drugmakers.
Statistics show that in the year leading up to last September, the UK sold medicines totaling billions to the US. This value accounted for 17.4% of all goods exports in that period.
"This deal protects jobs, stimulates funding and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," a government official commented.
Detailed NHS Changes
The agreement entails several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to double total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must return to the NHS to control costs will be capped at 15%. In the past, repayments were more than twenty percent.
Recent Tensions
This agreement takes place against a ongoing dispute between the drug companies and the UK government over drug pricing and regulatory access.
These tensions were heightened by arguments that US customers were paying a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while substantial investments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a percentage of its total funding over the last ten years.